



# ANUPAM RASAYAN INDIA LTD.

ARILSLDSTX20260213082

Date: February 13, 2026

To, <b>BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai -400001, India <b>SCRIP CODE: 543275</b>	To, <b>National Stock Exchange of India Limited</b> 'Exchange Plaza', C-1, Block-G, Bandra Kurla Complex, Bandra (East), Mumbai 400051, India <b>SYMBOL: ANURAS</b>
--	--

Dear Sir/ Madam,

**Subject: Clarification on Media Report: Regulation 30(11) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations").**

The Company has come across a report which has appeared on the news and electronic media today that the Company is planning to acquire a stake in Bliss GVS Pharma Ltd.

In view of the above speculation, we wish to clarify that there is no such material event/information that requires disclosure under Regulation 30 of the SEBI LODR Regulations and we do not wish to comment on any such speculation as has appeared in the said news report. The Company has complied with and continues to comply with the relevant disclosure norms under the SEBI LODR Regulations, as per the policy of the Company on disclosure of material events and information, as and when required.

We request you to please take this on record.

Thanking You,  
Yours faithfully,

**For, Anupam Rasayan India Limited**

**Ashish Gupta**  
Company Secretary and Compliance Officer